The Fred & Pamela Buffett Cancer Center has appointed Kathleen Moore, MD, as deputy director and director of Phase 1 oncology trials.
Dr. Moore is an internationally recognized leader in gynecologic oncology, known for her contributions to early-phase clinical trials and cancer research program development. In her role, Dr. Moore will provide strategic leadership across the cancer center as deputy director and will lead the Phase 1 Oncology Trials Program.
“My focus will be on expanding access to innovative early-phase studies, strengthening investigator-initiated and translational research, and accelerating the development of novel cancer therapeutics for patients,” Dr. Moore said.
Dr. Moore joins the Fred & Pamela Buffett Cancer Center from the Stephenson Cancer Center at the University of Oklahoma, where she most recently served as deputy director. Previously, she served as associate director for clinical research and director of the Oklahoma Tobacco Settlement Endowment Trust Phase 1 Drug Development Unit, leading the expansion of early-phase oncology trials, investigator-initiated drug development and multidisciplinary clinical research infrastructure.
“Dr. Moore’s appointment supports the cancer center’s strategic priorities as we work toward National Cancer Institute (NCI)-designated Comprehensive Cancer Center status by strengthening our national research profile and ensuring patients in Nebraska and the surrounding region have access to cutting-edge clinical trials,” said Joann Sweasy, PhD, director of the Fred & Pamela Buffett Cancer Center. “Her leadership will help bring new therapies to patients faster while advancing our mission to deliver patient-centered care and innovative research that benefit our community and beyond.”
A prolific investigator, Dr. Moore has authored more than 400 peer-reviewed publications in leading journals and has contributed to practice-changing advances in the treatment of ovarian, endometrial and cervical cancers. Her work has helped shape contemporary standards for drug development and clinical trial design in gynecologic oncology.
“I am honored to join the Fred & Pamela Buffett Cancer Center at such an important moment in its growth,” Dr. Moore said. “The center has a strong foundation in multidisciplinary cancer care and translational science, and I am deeply aligned with its mission to bring innovative therapies to patients through rigorous, patient-centered clinical research. I look forward to working with faculty, staff and trainees to expand early-phase trials and strengthen the center’s impact locally, nationally and internationally.”
Dr. Moore currently serves on the board of directors of the American Society of Clinical Oncology. She holds leadership positions within NRG Oncology, the Gynecologic Oncology Group Foundation and the International Gynecologic Cancer Research Consortia.
Dr. Moore received her medical degree from the University of Washington School of Medicine. She graduated with high honors and was elected to Alpha Omega Alpha. She completed her residency in obstetrics and gynecology at Magee-Womens Hospital of the University of Pittsburgh Medical Center, followed by fellowship training in gynecologic oncology and a Master of Science in Epidemiology at the University of Oklahoma Health Sciences Center.